Resolution Therapeutics congratulates University of Edinburgh on positive 4-year MATCH trial data on RMT in liver cirrhosis
Four-year follow-up data from the University of Edinburgh’s MATCH study, led by…
Infex Therapeutics announces positive Phase IIa results for RESP-X in non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa
Study met its primary objective demonstrating excellent safety and tolerability, of RESP-X…
Lifespan Vision Ventures Leads Violet Therapeutics’ $4.75M Seed Extension Financing
NORWALK, Conn., May 18, 2026 /PRNewswire/ -- Lifespan Vision Ventures (LVV), an…
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreichs Ataxia on Monday, May 18, 2026
May 17, 2026 16:00 ET | Source: Design Therapeutics, Inc. CARLSBAD, Calif.,…
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
- Stenoparib clinical development continues in relapsed small cell lung cancer and,…
Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress
Agoura Hills, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc.…
ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal…
Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer
European Hematology Association (EHA) oral presentation to report 67% hematological improvement, durable…
Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
May 08, 2026 20:45 ET | Source: Amplia Therapuetics Limited Melbourne, Australia,…
Orchard Therapeutics Awarded Innovation Passport Designation for OTL-201 in MPS-IIIA
LONDON, April 30, 2026 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a Kyowa Kirin…
